A new entity, the so-called triple negative (oestrogen receptor, progesterone receptor and HER2 negative) breast cancer has a highly aggressive clinical course with shorter recurrence-free and overall survival (Dent et al, 2007). The gene discussed is PGR; the disease is breast carcinoma.